ABT Abbott Laboratories

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

Abbott Laboratories (ABT) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 1.01: Entry into a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Abbott priced $20B in senior notes across 8 tranches — one of the largest investment-grade debt offerings in recent years
• Tranches range from 3-year floating rate to 40-year fixed at 5.600%, with longest-dated $3.75B tranche at 5.500% due 2056

+3 more insights

Other Abbott Laboratories 8-K Filings

8-K Mar 9, 2026

Get deeper insights on Abbott Laboratories

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.